FGFR2b Logo

FGFR2b is an emerging protein biomarker overexpressed in ~ 38%* of advanced gastric/GEJ cancer patients1

Overexpression of FGFR2b protein drives tumorigenesis2,3

Graph illustrating the rising number of prostate cancer patients, highlighting a concerning trend in cancer prevalence

FGFR2b protein overexpression may be prognostic and associated with shorter survival in gastric/GEJ cancers4

FGFR2b protein overexpression is distinct from FGFR2 gene amplification5-7

Gastric/GEJ cancer detected by IHC | Cholangiocarcinoma detected by NGS or PCR | Urothelial cancer detected by NGS or PCR
gene-amplification-mob
  • FGFR2b protein overexpression can occur in the absence of FGFR2 gene amplification where it is reported to occur in only 2%-9% of gastric cancers, measured by NGS/PCR6,7,9-12

FGFR2b protein: a biologically distinct splice isoform that influences cell behavior13

Diagram of FGFR2 gene splicing into FGFR2b and FGFR2c protein isoforms in epithelial and mesenchymal cells
fgfr2-family-mob
SEE HOW IHC STAINING CAN DETECT FGFR2b

*FGFR2b protein overexpression is defined as any percentage of tumor cells with moderate (2+) to strong (3+) membranous staining, as detected by IHC.1

CLDN18.2, claudin-18 isoform 2; CPS, combined positive score; dMMR, deficient mismatch repair; FGF, fibroblast growth factor; FGFR2, fibroblast growth factor receptor 2; FGFR2b, fibroblast growth factor receptor 2, isoform IIIb; FGFR2c, fibroblast growth factor receptor 2, isoform IIIc; FISH, fluorescence in situ hybridization; GEJ, gastroesophageal junction; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; NGS, next-generation sequencing; PCR, polymerase chain reaction; PD-L1, programmed cell death ligand 1.

References: 1. Rha SY, et al. JCO Precis Oncol. 2025;9:e2400710. 2. Turner N, et al. Nat Rev Cancer. 2010;10:116-129. 3. Khosravi F, et al. Front Cell Dev Biol. 2021;9:672935. 4. Ahn S, et al. Mod Pathol. 2016;29:1095-1103. 5. Sato Y, et al. J Clin Med. 2023;12:4646. 6. Han N, et al. Pathobiology. 2015;82:269-279. 7. Zhang J, et al. Cells. 2019;8:637. 8. Krook MA, et al. Br J Cancer. 2021;124:880-892. 9. Catenacci DVT, et al. J Clin Oncol. 2020;38:2418-2426. 10. De Luca A, et al. Int J Mol Sci. 2020;21:6856. 11. Li L, et al. J Gastrointest Oncol. 2022;13:77-83. 12. Wainberg ZA, et al. Lancet Oncol. 2022;23:1430-1440. 13. Warzecha CC, et al. Molecular Cell. 2009;33:591-601. 14. Chioni AM, et al. Cancers. 2021;13:5681. 15. Jimenez-Pascual A, et al. Cells. 2019;8:715.

References: 1. FPO 2. FPO 3. FPO